# CEO Phase 1 èª¿æŸ»çµæœå ±å‘Šæ›¸

**ä½œæˆæ—¥æ™‚**: 2025-07-02 17:37  
**ä½œæˆè€…**: CEO  
**èª¿æŸ»æ™‚é–“**: 17:35-17:37ï¼ˆ2åˆ†é–“ï¼‰  

---

## ğŸ“Š èª¿æŸ»çµæœã‚µãƒãƒªãƒ¼

### æ•°å€¤çš„ç™ºè¦‹
- **Ver2ä½¿ç”¨ã‚¯ãƒ©ã‚¹ç·æ•°**: 634å€‹ï¼ˆãƒ¦ãƒ‹ãƒ¼ã‚¯ï¼‰
- **æ—¢å­˜CSSå®šç¾©ç·æ•°**: 470å€‹
- **ver2-unified.csså®šç¾©æ•°**: 19å€‹
- **ä¸è¶³ã‚¯ãƒ©ã‚¹æ•°**: 608å€‹ï¼ˆ96%ãŒæœªå®šç¾©ï¼‰

### é‡è¦ãªç™ºè¦‹
1. **åŸºæœ¬æ§‹é€ ã‚¯ãƒ©ã‚¹ãŒã™ã¹ã¦æœªå®šç¾©**
   - basic-info-card
   - classification-badges
   - main-indications
   - quick-summary-student
   - student-faq-section
   - prescription-examples
   - level-btn
   - summary-grid

2. **æ—¢å­˜CSSãƒ•ã‚¡ã‚¤ãƒ«ã«å¯¾å¿œå®šç¾©ãªã—**
   - drug-detail.cssã«ã¯ç•°ãªã‚‹ã‚¯ãƒ©ã‚¹ä½“ç³»
   - Ver2ã¯å®Œå…¨ã«ç‹¬è‡ªã®ã‚¯ãƒ©ã‚¹æ§‹é€ ã‚’æ¡ç”¨
   - å…ƒã€…HTMLã«åŸ‹ã‚è¾¼ã¾ã‚Œã¦ã„ãŸCSSã‹ã‚‰æ¥ã¦ã„ã‚‹å¯èƒ½æ€§å¤§

---

## ğŸ” è©³ç´°èª¿æŸ»ãƒ‡ãƒ¼ã‚¿

### Ver2ã‚¯ãƒ©ã‚¹ã®ç‰¹å¾´
```
æœ€åˆã®20å€‹ï¼š
absorption-inhibitor
ace-arb-comparison
ace-inhibitor-cough
ace-preference
achievement-card
achievement-note
active
add-on-therapies
adherence-benefit
adoption-timeline
advanced-clinical-strategy
advanced-level
adverse-event-management
ae-classification
ae-management-protocols
affinity-table
after-era
after-jupiter
age-specific-considerations
ai-powered-optimization
```

ã“ã‚Œã‚‰ã®ã‚¯ãƒ©ã‚¹åã‹ã‚‰ã€Ver2ã¯ï¼š
- è–¬ç†å­¦çš„ãªè©³ç´°æƒ…å ±
- è‡¨åºŠæˆ¦ç•¥
- å‰¯ä½œç”¨ç®¡ç†
- AIæœ€é©åŒ–
ãªã©ã®é«˜åº¦ãªæ©Ÿèƒ½ã‚’æŒã¤ã“ã¨ãŒã‚ã‹ã‚Šã¾ã™ã€‚

### ä½¿ç”¨é »åº¦åˆ†æ
ã™ã¹ã¦ã®åŸºæœ¬æ§‹é€ ã‚¯ãƒ©ã‚¹ãŒ3ã¤ã®Ver2ãƒ•ã‚¡ã‚¤ãƒ«å…¨ã¦ã§ä½¿ç”¨ï¼š
- 100%ã®ä½¿ç”¨ç‡ = æœ€é‡è¦ã‚¯ãƒ©ã‚¹
- ãƒšãƒ¼ã‚¸æ§‹é€ ã®åŸºç›¤ã¨ãªã‚‹ã‚¯ãƒ©ã‚¹

---

## ğŸ¯ å„ªå…ˆåº¦åˆ†é¡ï¼ˆæš«å®šï¼‰

### P0: æœ€å„ªå…ˆï¼ˆåŸºæœ¬æ§‹é€ ï¼‰- ç´„30å€‹
```
basic-info-card
drug-name-displayï¼ˆå®šç¾©æ¸ˆã¿ï¼‰
classification-badges
main-indications
indication-list
quick-summary-student
student-faq-section
student-questions
prescription-examples
level-btn
level-indicator
summary-grid
summary-item
rx-example
rx-format
brand-name
generic-name
drug-class-badge
first-choice-badge
faq-note
```

### P1: é«˜å„ªå…ˆï¼ˆ3æ®µéšå­¦ç¿’ï¼‰- ç´„80å€‹
```
advanced-level
intermediate-level
practice-scenario
clinical-significance
expert-opinion
evidence-based
learning-points
case-study-content
pharmacist-note
clinical-pearls
```

### P2: ä¸­å„ªå…ˆï¼ˆè–¬å­¦å°‚é–€ï¼‰- ç´„200å€‹
```
molecular-discovery
cellular-effects
metabolic-effects
ampk-effects
angioedema-protocol
cardiovascular-protection
microbiome-changes
at1-pathway
```

### P3: ä½å„ªå…ˆï¼ˆè£…é£¾çš„ï¼‰- ç´„298å€‹
ãã®ä»–ã®è©³ç´°ãªæ©Ÿèƒ½ã‚¯ãƒ©ã‚¹

---

## ğŸ’¡ é‡è¦ãªæ´å¯Ÿ

### @importã®å…ƒæ§‹é€ ï¼ˆæ¨æ¸¬ï¼‰
Ver2ã¯å…ƒã€…ä»¥ä¸‹ã®ã‚ˆã†ãªæ§‹é€ ã ã£ãŸå¯èƒ½æ€§ï¼š
1. HTMLã«`<style>`ã‚¿ã‚°ã§977è¡Œã®CSSåŸ‹ã‚è¾¼ã¿
2. ã“ã‚Œã‚’å¤–éƒ¨åŒ–ã™ã‚‹éš›ã«ver2-unified.cssã‚’ä½œæˆ
3. ã—ã‹ã—ã€åŸ‹ã‚è¾¼ã¿CSSã®å†…å®¹ã‚’ç§»æ¤ã›ãšã«å‰Šé™¤
4. çµæœã¨ã—ã¦608å€‹ã®ã‚¯ãƒ©ã‚¹ãŒå¤±ã‚ã‚ŒãŸ

### è§£æ±ºã®æ–¹å‘æ€§
1. **å…ƒã®åŸ‹ã‚è¾¼ã¿CSSã®å¾©å…ƒã¯ä¸å¯èƒ½**ï¼ˆãƒãƒƒã‚¯ã‚¢ãƒƒãƒ—ãªã—ï¼‰
2. **æ–°è¦ã«ã‚¯ãƒ©ã‚¹å®šç¾©ã‚’ä½œæˆã™ã‚‹å¿…è¦**
3. **HTMLã®æ§‹é€ ã‹ã‚‰æ¨æ¸¬ã—ã¦å®Ÿè£…**

---

## ğŸ“‹ æ¬¡ã®ã‚¢ã‚¯ã‚·ãƒ§ãƒ³

1. P0ã‚¯ãƒ©ã‚¹ã®è©³ç´°ãªæ§‹é€ åˆ†æ
2. å„ã‚¯ãƒ©ã‚¹ã«å¿…è¦ãªã‚¹ã‚¿ã‚¤ãƒ«å±æ€§ã®æ¨å®š
3. æ®µéšçš„ãªå®Ÿè£…é–‹å§‹

---

**èª¿æŸ»å®Œäº†æ™‚åˆ»**: 2025-07-02 17:37